ScreenerHero

VIVE Vivesto AB

STO · SE · Healthcare · Drug Manufacturers - Specialty & Generic · vivesto.com
8.340SEK-0.48%Mkt Cap: 8.83M $P/E: —

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for th…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$57.06BUSD
TEVA
Teva Pharmaceutical Industries Limited Ordinary Shares
$46.10BUSDP/E 65.9
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$38.70BUSDP/E 18.3
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
ZTS
Zoetis Inc. Class A Common Stock
$28.80BUSDP/E 11.4
UTHR
United Therapeutics Corporation - Common Stock
$23.23BUSDP/E 19.4
VTRS
Viatris Inc. - Common Stock
$20.22BUSD
SOBI
Swedish Orphan Biovitrum AB
$14.24BUSDP/E 109.4
NBIX
Neurocrine Biosciences, Inc. - Common Stock
$14.55BUSDP/E 21.0
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated Common Stock
$11.06BUSD
RDY
Dr. Reddy's Laboratories Ltd Common Stock
$10.20BUSDP/E 29.2
KRK
Krka, d. d.
$8.50BUSDP/E 18.4
AMRX
Amneal Pharmaceuticals, Inc. - Class A Common Stock
$7.07BUSDP/E 42.3
ALKS
Alkermes plc - Ordinary Shares
$7.00BUSDP/E 109.9
HIMS
Hims & Hers Health, Inc. Class A Common Stock
$6.77BUSD
LNTH
Lantheus Holdings, Inc. - Common Stock
$6.53BUSDP/E 23.9
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
$5.83BUSDP/E 76.6
INDV
Indivior Pharmaceuticals, Inc. - Common Stock
$4.21BUSDP/E 12.8

Key Statistics

Company
Market Cap8.83M USD
Enterprise Value6.58M USD
Revenue (TTM)765 USD
Gross Profit765 USD
Net Income (TTM)-3.26M USD
Revenue/Share0.0010 SEK
Last Price8.340 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0028925701
Valuation
P/E (Trailing)—
P/E (Forward)-83.40
PEG—
EV/EBITDA-2.23
EV/Revenue8602.65
P/S11541.90
P/B35.95
EPS (TTM)-4.12
EPS (Forward)-0.10
52W Range
7.0006% of range27.76
52W High27.76 SEK
52W Low7.000 SEK
Profitability
Gross Margin100.00%
Oper. Margin-107825.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-27.36%
ROA-22.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.25M USD
CapEx (TTM)942.27K USD
FCF Margin-222859.38%
FCF Yield-19.31%
Net Debt-2.25M USD
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity0.10
Current Ratio2.48
Quick Ratio2.39
Book Value/Sh0.23 SEK
Cash/Share2.12 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateMay 20, 2026
Analyst Consensus
Rating—
Target (Mean)24.00 SEK
Upside (mean)+187.8%
Target Range24.00 SEK – 24.00 SEK
# Analysts1
Ownership
Shares Out.11.07M
Float6.34M
Insiders47.33%
Institutions10.20%
Technical
SMA 508.848 (-5.7%)
SMA 2009.006 (-7.4%)
Beta0.93
S&P 52W Chg14.58%
Avg Vol (30d)11.68K
Avg Vol (10d)6.35K
Technical Indicators
RSI (14)40.6
MACD-0.1957
MACD Signal-0.1691
MACD Hist.-0.0266
BB Upper9.160 SEK
BB Middle8.727 SEK
BB Lower8.294 SEK
BB Width9.92%
ATR (14)0.5198 SEK
Vol Ratio (20d)0.33x